What BPC-157 and TB-500 is
BPC-157 and TB-500 are two separate peptides. This page is for a vial that holds both, which is sold as a blend. FDA's review of BPC-157 says a website mentions products with BPC-157 and TB-500 for research purposes only and not for human or veterinary use.
BPC-157 is short for Body Protection Compound. FDA's review says it's reported to be made of 15 amino acids. It gives the formula of the free base as C62H98N16O22 and its molecular weight as 1419.5 g/mol, and describes it as a white to off-white lyophilized powder.
FDA's review of TB-500 says the free base is understood today to be a synthetic fragment of thymosin beta-4 that's seven amino acids long, with an acetyl group on one end. It gives the formula as C38H68N10O14 and the molecular weight as 889.01 g/mol, and says it's reported as a white to off-white solid. The review also says several websites often use the names thymosin beta-4 and TB-500 interchangeably, and that the two are not the same substance.
FDA says of each that its name is a common name and not a United States Adopted Name, and that it has encountered multiple salts and derivatives sold commercially under the same common name. No document behind this page defines a blend of the two, so this page can't know what a vial holds. The amounts printed on your own vial's label are what count.
Where it stands with the FDA
Neither peptide is approved by the FDA, and the agency says neither is a component of any FDA-approved drug. Both reached the FDA because they were nominated for the list of substances that can be used in compounding. Those nominations were later withdrawn, and FDA reviewed each peptide on its own initiative, in two separate documents.
FDA evaluated BPC-157 for one use, ulcerative colitis. The products in the nominations included an injection under the skin at 2,000 mcg/mL. The review concluded that the criteria weigh against putting BPC-157 on the list, and proposed not adding it. It considers the substance not well characterized, and it's concerned about the potential for immune reactions to it in an injection. It also says there's insufficient clinical safety information. It found no studies that gave BPC-157 to humans by mouth, under the skin, through the nose or through the skin. It did identify two studies that gave it as a rectal enema, for a maximum of two weeks.
FDA evaluated TB-500 for wound healing. The product in the nomination was a 3 mg/mL lyophilized powder for injection under the skin or into muscle. Here too the review concluded that the criteria weigh against putting it on the list, and proposed not adding it. It says TB-500 isn't well characterized, that it's concerned about the potential for immune reactions to it in an injection, and that it has not identified any clinical studies or human exposure data using TB-500. For that reason it calls the potential safety risks of using it in humans unknown.
Neither review weighs the two together as one product, but each mentions products that hold both. FDA's review of BPC-157 describes a report in its adverse event database from a woman who injected, under the skin, a product containing BPC-157 and TB-500 that was labeled for "research purposes only". She developed diffuse hyperpigmentation and darkening of the gums after using it for one week, and identical reactions when she went back to it. FDA wrote that the reactions were likely due to the product, and that because the product contained two peptides it is not possible to assess a potential relationship between BPC-157 and the reactions. FDA also notes that with reports in that database there is no certainty that the reported event was due to the product.
FDA's review of TB-500 says a search of its complaint system for food, dietary supplements and cosmetics retrieved two cases about "blended TB-500 and BPC-157", and that the reports did not include safety assessments.
FDA's page on substances that may present significant safety risks, current as of April 22, 2026, lists both peptides among the substances that were previously in category 2 and were withdrawn by their nominators. It lists TB-500 as "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500". It says compounded drugs containing either one may pose risk for immunogenicity for certain routes of administration. Neither name is on FDA's list of nominated substances as updated May 14, 2026.
Neither proposal is a final decision. Both reviews were written for FDA's Pharmacy Compounding Advisory Committee, and both say FDA will not issue a final determination until input from the advisory committee process has been considered and all reviews have been finalized. FDA put both peptides on that committee's agenda for July 23, 2026. Its meeting page had no minutes posted as of October 2026, so this page doesn't report a vote.
Storing BPC-157 and TB-500
The storage figures in FDA's two reviews are reports about each bulk substance by itself. None is about the two mixed in one vial.
For BPC-157, the review says it's recommended that the lyophilized free base be stored desiccated, which means kept dry, below -18°C, because exposure to moisture will greatly decrease the long-term stability of lyophilized peptides. For BPC-157 acetate it says that, as reported in the literature, it's expected to be stable under reported storage conditions below -20°C.
For TB-500, the review says the free base is reported to be stable below -20°C under reported storage conditions, which it gives as sealed storage, away from moisture and light, under nitrogen. It says TB-500 acetate is reported to be stable below -15°C, protected from light and kept in a tightly closed container.
The reviews also repeat reports about each peptide alone in solution, and those aren't about a blend either. Both say that how stable a peptide stays depends heavily on how the finished product was made.
There's no approved label for either peptide, so there's no label to say how long a mixed vial keeps.
BPC-157 and TB-500 dosage calculator questions
How do I turn a BPC-157 and TB-500 dose into syringe units?
Pick the peptide your dose is of, divide that dose by that peptide's concentration to get millilitres, then multiply by 100. The same draw carries the others along in proportion. A vial with 5 mg of BPC-157 and 5 mg of TB-500 mixed with 2 mL holds 2.5 mg/mL of BPC-157 and 2.5 mg/mL of TB-500, so ten units hold 250 mcg of BPC-157 and 250 mcg of TB-500.
How much bacteriostatic water goes in a BPC-157 and TB-500 vial?
There's no single right amount. The water sets the concentration of every peptide in the vial at once, and changes none of the amounts. Choose the amount that puts your dose somewhere between about 10 and 40 units, where it's easiest to read.
Is BPC-157 and TB-500 approved by the FDA?
No. FDA says neither BPC-157 nor TB-500 is a component of any FDA-approved drug. It reviewed each for use in compounded drugs, concluded the criteria weigh against both and proposed not adding either to the list, then put them on an advisory committee's agenda for July 23, 2026. FDA says that isn't a final determination.
Does this page tell me how much BPC-157 and TB-500 to take?
No. Neither peptide is a component of any FDA-approved drug, so there's no approved dose of either to point to. The dose box is empty until you fill it in, and the chart only converts.
How much of each peptide is in a BPC-157 and TB-500 blend vial?
This page can't tell you. A blend is named by whoever sells it, and no document behind this page defines one. Type in the amount of each peptide printed on your own vial's label. The amounts in this page's worked example are only an example.
Can I work from a dose of either peptide?
Yes. Pick the peptide your dose is of and the page works out the draw from that one, then shows how much of the other peptide the same draw holds. Both are dissolved in the same water, so one draw can't be set to a separate dose of each. The second amount follows from the first.
Has the FDA reviewed BPC-157 and TB-500 together?
Not as one product. FDA reviewed each peptide in its own document, concluded the criteria weigh against both and proposed not adding either to the list. Its BPC-157 review describes one adverse event report about a product containing both, and says that because the product contained two peptides it is not possible to assess a potential relationship between BPC-157 and the reactions. Its TB-500 review mentions two complaint cases about the blend, and says the reports did not include safety assessments.
More peptide calculators by name
The same instrument, set up one peptide at a time. For any other vial, use the peptide reconstitution calculator.